Stöger H, Bauernhofer T, Moser R, Derstvenscheg E, Schmid M, Ploner F, Pakisch B, Wilders-Truschnig M, Haas J, Steindorfer P
Abteilung für Onkologie, Medizinische Universitätsklinik, Graz.
Wien Klin Wochenschr. 1994;106(18):575-80.
A retrospective review of male patients suffering from breast cancer seen over an 18-year period was carried out at the Department of Clinical Oncology of the University Hospital of Graz. Thirty evaluable cases were analysed. Eight patients had Stage I, 11 had Stage II, 8 had Stage III, and 3 had Stage IV disease. Local control was achieved in the majority, 29/30 (97%), by either surgery alone or combined surgery and radiation therapy. Local recurrence developed in 2 (7%) patients. Further 7 (23%) patients developed distant metastases and were treated in accordance with policies developed for the appropriate stage of the disease in females, with hormonal manipulation for hormone receptor-positive and -unknown patients and chemotherapy for hormone receptor-negative patients. The corrected five-year survival (Kaplan-Meier) is 83% for the entire group, 100% for patients with Stage I disease, 86% in Stage II, and 67% in Stage III and IV disease, respectively. This corresponds well with the results in recently published series. Stage of disease at initial presentation was a significant factor determining survival in our investigation. Our own data as well as recent data from literature suggest that with respect to TNM Stages in mammary carcinoma, there is no prognostic difference between men and women. To what extent improved local control by adequate local therapy or systemic adjuvant treatment modalities may improve overall survival remains to be discussed.
格拉茨大学医院临床肿瘤学系对18年间收治的男性乳腺癌患者进行了回顾性研究。分析了30例可评估病例。8例为I期,11例为II期,8例为III期,3例为IV期疾病。大多数患者(29/30,97%)通过单纯手术或手术联合放疗实现了局部控制。2例(7%)患者出现局部复发。另有7例(23%)患者发生远处转移,并根据针对女性疾病相应阶段制定的策略进行治疗,激素受体阳性和未知的患者采用激素治疗,激素受体阴性的患者采用化疗。整个组的校正五年生存率(Kaplan-Meier法)为83%,I期疾病患者为100%,II期为86%,III期和IV期疾病分别为67%。这与最近发表的系列研究结果相符。在我们的研究中,初始就诊时的疾病分期是决定生存的一个重要因素。我们自己的数据以及最近文献中的数据表明,就乳腺癌的TNM分期而言,男性和女性之间没有预后差异。通过适当的局部治疗或全身辅助治疗方式改善局部控制在多大程度上可以提高总体生存率仍有待讨论。